Compare Diageo plc (DEO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Medpace Holdings Inc — how do they compare? Diageo plc trades at $93.24 (market cap $53.05B), while Medpace Holdings Inc trades at $598.73 (market cap $16.90B). The key difference: Diageo plc is far larger — about 3.1× Medpace Holdings Inc's market cap, and Diageo plc pays a 3.5% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| DEO | MEDP | |
|---|---|---|
Market Cap | $53.05B | $16.90B |
Sector | Technology | Technology |
52-Week High | $115.33 | $620.59 |
52-Week Low | $72.47 | $393.42 |
Enterprise Value | $72.54B | $16.52B |
Dividend Yield | 3.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.61, down 3.6% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. A new $1 billion savings plan and focus on spirits and Guinness aim to drive a turnaround, with cash flow from operations strong at $4.4 billion in 2026.
The outlook is cautiously optimistic, with analyst consensus leaning buy (49%) amid execution of the cost-cutting strategy. Risks include North America weakness and competitive pressures, but valuation metrics like P/E of 30.5 reflect growth expectations. The stock offers potential for recovery if management delivers on efficiency gains and market share stabilization.
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
